Table 1

Summary of clinical characteristics and trans vivo delayed-type hypersensitivity responses of the patient cohort

Anergy	Bystander suppression	Patient number	Histology	Smoking history	Stage	Tumor PD-L1 expression (by 22C3)	TMB status	eGFR status	ALK status	ROS-1 status	Lines of systemic therapy	Treatment status	Disease status
No	Yes	10	Ad	Yes	IVA	High	Unknown	Negative	Negative	Negative	3	Pembrolizumab (1L), clinical trial of sitravatinib and nivolumab (2L), chemotherapy (3L)	Initial response to 2L treatment, then PD
Yes	Yes	2	Sq	Yes	IIIB	Low	Unknown	Negative	Negative	Negative	2	Palliative radiation	PD, deceased
Yes	Yes	7	Ad	No	IV	High	Unknown	Negative	Negative	Negative	0	None	PD, deceased
Yes	No	1	Ad	Yes	IV	Low	Indeterminate	Negative	EML4 fusion	Negative	2	Alectinib	Response
Yes	No	8	Ad	Yes	IV	High	Intermediate (14 mut/Mb)	Negative	Negative	Negative	2	Pembrolizumab for first primary, chemoradiation and durvalumab consolidation for second primary	CR in first, response and SD in second primary
Yes	No	9	Sq	Yes	IIIA	Unknown	Unknown	Unknown	Unknown	Unknown	1	Chemoradiation and durvalumab consolidation	Response
Yes	No	4	Ad (lepidic)	Yes	III	Low	Unknown	Negative	Negative	Unknown	2	Carboplatin, pemetrexed, pembrolizumab (1L)	PD, deceased
Yes	No	5	Ad	Yes	IV	Negative	Unknown	Negative	Negative	Negative	7	Nivolumab (4L), clinical trial of ipilimumab/MGA271 (6L)	PD, deceased
Yes	No	6	Sq	No	IV	High	Intermediate (11 mut/Mb)	Negative	Negative	Negative	2	Pembrolizumab (1L), clinical trial of anti-PD1 and anti-TIM3 blockade (2L)	PD, deceased

The patients demonstrating both anergy and bystander suppression are highlighted.
Ad, adenocarcinoma; ALK, anaplastic lymphoma kinase; CR, complete response; eGFR, Epidermal Growth Factor; 1L, first-line therapy; 2L, second-line therapy; 3L, third-line therapy; 4L, fourth-line therapy; 6L, sixth-line therapy; PD, progressive disease; PD-L1, Programmed Death Ligand 1; ROS-1, ROS proto-oncogene 1; SD, stable disease; Sq, squamous; TMB, tumor mutational burden.